Obstetric Cholestasis Nursing Guide

Definition — Intrahepatic Cholestasis of Pregnancy (ICP)

ICP (also called obstetric cholestasis) is a pregnancy-specific liver disorder characterised by:

Intense pruritus — typically palms and soles; worse at night; often debilitating
Raised serum bile acids ≥10 μmol/L
No primary skin rash — only secondary scratch marks (excoriations)
Often associated with raised ALT/AST (deranged LFTs)
Resolves spontaneously within days to weeks after delivery

ICP is a diagnosis of EXCLUSION. Other causes of pruritus in pregnancy (PUPPP, pemphigoid gestationis) and other causes of deranged LFTs must be excluded.

Bile Acid Thresholds

Bile Acid Level	Classification	Significance
<10 μmol/L	Normal	Does not meet diagnostic threshold for ICP
10–39 μmol/L	Mild–moderate ICP	Symptomatic; treat with UDCA; monitor
≥40 μmol/L	Severe ICP	Significantly increased foetal risks; consider earlier delivery
≥100 μmol/L	Very severe ICP	Highest stillbirth risk; delivery usually recommended 35–36 weeks

Epidemiology and Risk Factors

Prevalence: 0.5–1% of pregnancies in European populations; higher in South American (Chile up to 15%), Scandinavian, and South Asian populations
Risk factors: previous ICP (recurrence 45–90%), family history, multiple pregnancy, hepatitis C, cholestatic liver disease
Genetic component: variants in hepatic transport genes (ABCB4, ABCB11)
Oestrogen triggers cholestasis — explains winter seasonality and increased risk with twins (higher oestrogen)

Diagnosis and Investigations

Serum bile acids (fasting preferred — most accurate) — diagnostic if ≥10 μmol/L
LFTs (ALT, AST, ALP, GGT, bilirubin) — may be elevated but not always
Clotting studies (prothrombin time) — fat malabsorption → vitamin K deficiency → coagulopathy
Hepatitis B, C serology — to exclude viral hepatitis
Liver ultrasound — to exclude gallstones (more common in pregnancy)
Autoimmune screen if indicated (AMA, ANA, smooth muscle antibody)

CTG (cardiotocography) is NOT a reliable predictor of foetal compromise in ICP. Bile acids exert direct toxic effects on the foetal heart causing arrhythmias — these may be sudden and not preceded by CTG changes.

Symptom Assessment

Itch onset and distribution (palms/soles = characteristic; generalised is less specific)
Nocturnal worsening — significant symptom burden and sleep deprivation
Jaundice — present in only 10–15% of ICP cases
Dark urine, pale stools — cholestatic features
Foetal movement monitoring — women should be taught kick counting and report any reduction
Itch severity scoring: NRS 0–10 for symptom monitoring

Ursodeoxycholic Acid (UDCA)

UDCA (ursodeoxycholic acid) is the TREATMENT OF CHOICE for ICP. It reduces bile acid levels, improves LFTs, and reduces maternal pruritus. Evidence suggests improved foetal outcomes.

Dose: 10–15 mg/kg/day in divided doses (typically 500mg BD or TDS)
Mechanism: replaces hydrophobic toxic bile acids with hydrophilic UDCA; protects hepatocytes and placenta
Monitor bile acids and LFTs every 1–2 weeks
Generally well tolerated; side effects: diarrhoea, nausea (uncommon)
Stop UDCA after delivery — ICP resolves postpartum

AVOID antihistamines for ICP pruritus — they are INEFFECTIVE for cholestatic itch (no histamine mechanism). Calamine may provide temporary superficial relief only.

Timing of Delivery

Bile Acid Level	Recommended Delivery Timing
<40 μmol/L (mild)	37–38 weeks (consider induction; discuss with woman)
40–99 μmol/L (severe)	35–37 weeks — individualised decision; weigh stillbirth risk vs prematurity
≥100 μmol/L (very severe)	35–36 weeks — highest stillbirth risk; earlier delivery recommended

Delivery is the CURE for ICP. Induction should be offered after informed discussion about the balance of risks (stillbirth risk from ICP vs prematurity risk from early delivery).

Postpartum Care

ICP resolves within days to a few weeks after delivery — reassure women
Stop UDCA after delivery
Repeat LFTs and bile acids 6–8 weeks postpartum to confirm resolution
If LFTs do NOT normalise: investigate for underlying liver disease (PBC, PSC, viral hepatitis)
Counsel on recurrence risk (45–90% in subsequent pregnancies)
AVOID oestrogen-containing contraception (combined pill, patch, ring) — may trigger recurrence or worsen liver disease
Progestogen-only contraception is safe

Foetal Risks

Stillbirth is the most feared complication of ICP. Risk is highest with bile acids ≥100 μmol/L. The mechanism involves direct bile acid toxicity to the foetal myocardium causing fatal arrhythmia.

Stillbirth — predominantly in severe ICP (bile acids ≥40 μmol/L, especially ≥100)
Preterm labour — spontaneous preterm labour increased in ICP
Meconium-stained liquor — increased risk; bile acids stimulate foetal gut motility
Foetal distress in labour — monitor closely; continuous CTG in labour recommended
Neonatal morbidity — from prematurity if delivered early

Maternal Risks

Vitamin K deficiency — fat malabsorption; check clotting; oral vitamin K supplementation
Postpartum haemorrhage risk — from coagulopathy
Gallstone disease — increased risk in women with ICP
Future liver disease — ICP is associated with increased risk of gallstones, non-alcoholic liver disease, hepatitis C (if positive)
Psychological impact — severe itch causes significant sleep deprivation, anxiety, and distress

ICP in the GCC

ICP is underdiagnosed in some GCC settings — pruritus in pregnancy may be attributed to skin dryness, heat, or stretching
GCC climate: extreme heat and dehydration may worsen pruritus symptoms
South Asian communities (significant in UAE, Qatar, Kuwait) have higher ICP prevalence — important for risk stratification
DHA antenatal guidelines in Dubai include bile acid screening for women presenting with unexplained pruritus in pregnancy
LFTs are routinely checked in GCC antenatal care — facilitates incidental ICP detection

Cultural Considerations

Some women may attribute pruritus to heat, skin changes, or spiritual causes — screen proactively rather than waiting for self-referral
Night-time pruritus may be attributed to "bad dreams" or cultural beliefs — explore sensitively
Extended family may advise home remedies — ensure women know antihistamines are ineffective and potentially unhelpful
Oestrogen-containing contraception avoidance must be communicated clearly postpartum with suitable alternatives offered

UDCA Availability and Prescribing in GCC

UDCA is available in UAE (DHA/DOH formulary), Saudi Arabia (SFDA approved), Qatar, and Kuwait
Brand names vary: Ursofalk, Actigall, Urso — same drug
Nurses should counsel on dose compliance — twice or three times daily dosing; take with food
Monitor efficacy: repeat bile acids and LFTs every 1–2 weeks during treatment

High-Yield Exam Points

ICP: pruritus (palms/soles, worse at night) + bile acids ≥10 μmol/L + NO primary rash
Severe ICP = bile acids ≥40 μmol/L; highest stillbirth risk at ≥100 μmol/L
UDCA = treatment (reduces symptoms AND improves foetal outcomes)
Antihistamines are INEFFECTIVE for cholestatic itch — do NOT use as primary treatment
CTG is NOT reliable for predicting foetal compromise in ICP
Induction: mild ICP 37–38w; severe 35–37w; bile acids ≥100 = 35–36w
ICP resolves within days of delivery; stop UDCA postpartum
Repeat LFTs at 6–8 weeks to confirm resolution
Avoid oestrogen contraception; recurrence risk 45–90%

Common Exam Traps

ICP pruritus has NO primary rash — only scratch marks. A primary rash = different diagnosis (PUPPP etc.)
CTG does NOT reliably predict ICP stillbirth — sudden foetal death from arrhythmia can occur without warning
Antihistamines are NOT effective for ICP itch — they do not work via histamine mechanism in cholestasis
Oestrogen contraception is CONTRAINDICATED postpartum in women with ICP history

GCC Clinical Practice Insights

DHA Antenatal Bile Acid Screening Protocol +

Dubai Health Authority antenatal guidelines recommend checking serum bile acids (ideally fasting) in any pregnant woman presenting with unexplained pruritus, particularly involving palms and soles. LFTs are checked simultaneously. Results are reviewed by the obstetric team within 48 hours. Women with elevated bile acids are referred to the foetal medicine / obstetric consultant for ICP management.

Heat and Dehydration Worsening ICP Symptoms +

GCC's extreme summer heat (45–50°C) causes excessive sweating, dehydration, and increased skin sensitivity — all of which can worsen pruritus in ICP. Women with ICP should be advised to stay in air-conditioned environments, maintain adequate hydration, wear loose-fitting cotton clothing, and avoid hot showers. Cool baths with emollient may provide symptomatic relief for the skin.

South Asian Population and Higher ICP Prevalence +

South Asian communities (Pakistani, Indian, Bangladeshi, Sri Lankan origin) have a higher ICP prevalence than European populations. Given that South Asians constitute a large proportion of the expat workforce in the UAE, Qatar, and Kuwait, antenatal teams should maintain a high index of suspicion for ICP in this population group, particularly in the third trimester.

Postpartum Contraception Counselling in GCC +

The combined oral contraceptive pill (COCP) and other oestrogen-containing contraceptives are contraindicated in women with a history of ICP. Nurses providing postpartum contraceptive counselling should document the ICP diagnosis and advise progestogen-only options (mini-pill, implant, DMPA injection, LNG-IUS). This is particularly important as many women in GCC desire rapid return to contraception post-delivery.

Practice MCQs

Q1. A 32-week pregnant woman presents with intense itching of her palms and soles, worse at night. Examination shows scratch marks but no primary rash. Bile acids return at 45 μmol/L. What is the diagnosis?

Correct answer: B — This is classic severe ICP: pruritus of palms/soles (worse at night), no primary rash (scratch marks only), bile acids ≥40 μmol/L = severe. UDCA should be started, and delivery planning at 35–37 weeks discussed. Antihistamines are ineffective for cholestatic itch. PUPPP has a primary rash (urticarial papules).

Q2. A woman with ICP and bile acids of 55 μmol/L at 36 weeks asks why she cannot wait until 40 weeks for delivery. What is the most accurate explanation?

Correct answer: C — Severe ICP (bile acids ≥40 μmol/L) significantly increases stillbirth risk. The mechanism (bile acid toxicity causing fatal foetal cardiac arrhythmia) means CTG cannot reliably detect this risk in advance. Earlier delivery reduces stillbirth risk while balancing neonatal prematurity risk. RCOG guidelines support delivery at 35–37 weeks for severe ICP.

Q3. Which treatment is first-line for ICP-related pruritus?

Correct answer: C — UDCA is the evidence-based first-line treatment for ICP. It reduces serum bile acids, improves LFTs, and reduces pruritus. Antihistamines (chlorphenamine, hydroxyzine) are INEFFECTIVE for cholestatic itch as it is not histamine-mediated. Calamine may provide minimal topical comfort but does not treat the underlying condition.

Q4. A woman is discharged home 5 days after delivery. She had ICP during pregnancy with bile acids of 62 μmol/L. Which contraceptive should be AVOIDED?

Correct answer: C — Oestrogen-containing contraceptives (COCP, combined patch, vaginal ring) are CONTRAINDICATED in women with a history of ICP. Oestrogen can trigger cholestasis and may cause recurrence. Progestogen-only methods (mini-pill, implant, DMPA, LNG-IUS) are all safe alternatives.